

References

I-202

1. Dai J, Almazan TH, Hong EK, Khodadoust MS, Arai S, Weng W, et al. Potential association of anti-CCR4 antibody mogamulizumab and graft-vs-host disease in patients with mycosis fungoides and sezary syndrome. *JAMA Dermatology*. 2018;154(6):728-730.
2. National Organization for Rare Disorders (NORD). Cutaneous T-Cell Lymphomas. 2013.
3. MICROMEDEX®SOLUTIONS Compendia. 2021.Mogamulizumab-kpkc.
4. Clinical Pharmacology Compendia. [database online]. 2021. Tampa FL: Gold Standard, Inc. Mogamulizumab-kpkc.
5. Poteligeo® (Mogamulizumab-kpkc) injection, for intravenous use [package insert]. Bedminster, NJ. Kyowa Kirin, Inc. Revised 08/2018.
6. National Comprehensive Cancer Network (NCCN). Mogamulizumab-kpkc. NCCN Drugs and Biologics Compendium®. 2021.
7. Scarisbrick J, Geskin LJ, Bagot M, et al. Efficacy of mogamulizumab in previously treated patients with less advanced mycosis fungoides: results from the mavoric study. *Hematological Oncology*. 2019;37:6667.
8. Phillips AA, Fields PA, Hermine O, et al. Mogamulizumab versus investigator's choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma. *Haematologica*. 2019;104(5):993-1003.
9. Mogamulizumab-kpkc. In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated March 9, 2020.
10. Mogamulizumab. Lexi-Drugs. Hudson, OH: Lexicomp, 2021.
11. Kim YH, Bagot M, Pinter-Brown L, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. *Lancet Oncol*. 2018;19(9):1192-1204.